News and updates

Agendia Announces Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology

June 20, 2019

  PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 20 June 2019 – Agendia, Inc., a world leader in precision oncology, announced today the open access publication of MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology in the Journal of Molecular Diagnostics. The publication summarized the analytical and clinical validation studies…

Read more

BluePrint® Identifies Genomic Subtypes for African-American Breast Cancer Patients with Low Risk Outcomes

June 3, 2019

PRESS RELEASE New data presented at ASCO underscores importance of genomic profiling for African-American women with breast cancer whose unique tumor biology can sometimes lead to poorer prognoses   IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 1 June 2019 – Agendia, Inc., a world leader in precision oncology, today announced the presentation of study results…

Read more

Agendia Appoints Two Industry Veterans to Board of Directors

May 31, 2019

PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 31 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today the appointment of industry veterans Laurie Heilmann and François Ferré, Ph.D. to its board of directors. With more than 30 years of executive leadership experience, Laurie Heilmann is the former president of…

Read more

Agendia and Imegen Announce an Exclusive Distribution Agreement for MammaPrint® and BluePrint® in Spain and Portugal

May 21, 2019

PRESS RELEASE IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS – 21 May 2019 – Agendia, Inc., a world leader in precision oncology, announced today an agreement with Imegen (Valencia, Spain), for the exclusive distribution of the MammaPrint® and BluePrint® breast cancer genomic tests throughout Spain and Portugal. MammaPrint, which has extensive clinical validation, uses the proprietary,…

Read more